Tema Etfs LLC Increases Position in Becton, Dickinson and Company $BDX

Key Points

• Tema Etfs LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 144.3%, acquiring an additional 1,330 shares and now owning a total of 2,252 shares valued at $516,000.
• Other institutional investors have also significantly increased their stakes, with Brighton Jones LLC raising its position by 98.2% and Wealth Enhancement Advisory Services LLC increasing its stake by 50.6% in the first quarter.
• Becton, Dickinson & Company's recent quarterly earnings exceeded expectations, reporting $3.68 EPS, with revenues of $5.51 billion, indicating a 10.4% year-over-year growth.

Tema Etfs LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 144.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,252 shares of the medical instruments supplier's stock after purchasing an additional 1,330 shares during the period. Tema Etfs LLC's holdings in Becton, Dickinson and Company were worth $516,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. GQG Partners LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $689,833,000. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after acquiring an additional 1,259,750 shares during the last quarter. Nuveen LLC purchased a new stake in Becton, Dickinson and Company in the first quarter worth $211,097,000. GAMMA Investing LLC raised its stake in Becton, Dickinson and Company by 29,654.0% in the 1st quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier's stock valued at $170,523,000 after acquiring an additional 741,943 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after buying an additional 667,957 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Down 2.5%

Becton, Dickinson and Company stock traded down $4.88 during trading hours on Tuesday, reaching $188.11. The company had a trading volume of 994,630 shares, compared to its average volume of 2,606,952. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company has a 50-day moving average price of $183.53 and a 200 day moving average price of $193.61. The firm has a market cap of $53.92 billion, a price-to-earnings ratio of 33.83, a P/E/G ratio of 1.44 and a beta of 0.27. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Analysts Set New Price Targets

Several research analysts have commented on the company. Morgan Stanley raised their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Barclays cut their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Citigroup cut Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Piper Sandler reiterated a "neutral" rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average target price of $211.44.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $192.30, for a total transaction of $165,954.90. Following the transaction, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. This represents a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.